Purpose: Teprotumumab, an insulin-like growth factor 1 receptor monoclonal antibody, is
FDA-approved to treat thyroid eye disease (TED). The initial clinical trials excluded patients …

Thyroid eye disease (TED) is a complex autoimmune condition that can cause proptosis,
ophthalmoplegia, diplopia, optic nerve compression, and vision loss. These clinical findings …

Purpose Thyroid eye disease (TED) is a progressive, debilitating and potentially vision-
threatening autoimmune disease. Teprotumumab, a novel human monoclonal antibody, has …

Purpose: This study analyzed the degree and timing of proptosis regression after
teprotumumab therapy. Methods: A retrospective study of all patients who completed 8 …

Thyroid-associated ophthalmopathy (TAO) is an autoimmune component of Graves' disease
for which no currently available medical therapy provides reliable and safe benefit. Based …

Importance Thyroid eye disease can be a debilitating autoimmune disorder characterized by
progressive proptosis or diplopia. Teprotumumab has been compared with placebo in …

Context Teprotumumab therapy for thyroid eye disease (TED) patients represents a major
step forward. It targets and inhibits the insulin-like growth factor-1 receptor (IGF-1R), and its …

Purpose To report the case of a patient with reactivated, refractory thyroid eye disease (TED)
treated with teprotumumab. Observations A 51-year-old female with a 16-year history of …

Purpose: In response to the coronavirus (COVID-19) pandemic, teprotumumab production
was temporarily halted with resources diverted toward vaccine production. Many patients …

Thyroid Eye Disease (TED) is a debilitating autoimmune condition often associated with
thyroid dysfunction, leading to significant ocular and orbital morbidity. This review explores …